YD Bio Ltd YDES
YD Bio Ltd (Nasdaq: YDES) is an oncology diagnostics company. Its next catalyst on record is 3D LensMate Eye Drops (exosomes) / LSC Eye Drug: Complete Phase I clinical trials (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: 3D LensMate Eye Drops (exosomes) / LSC Eye Drug — Complete Phase I clinical trials (2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| 3D LensMate Eye Drops (exosomes) | dry eye | biologic-other | Pre-clinical |
| LSC Eye Drug/Injection (exosome-based) | AMD, macular edema, neovascular glaucoma | biologic-other | Pre-clinical |
| Breast cancer blood test (de novo, Class II) | breast cancer | — | NA_NON_THERAPEUTIC |
| Pancreatic cancer blood test (ZFP30 methylation) | pancreatic cancer | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.